This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of Epigallocatechin-Gallate on Inner Retinal Function in Ocular Hypertension and Early Glaucoma

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2007 by Catholic University of the Sacred Heart.
Recruitment status was:  Recruiting
Information provided by:
Catholic University of the Sacred Heart Identifier:
First received: May 18, 2007
Last updated: NA
Last verified: May 2007
History: No changes posted
The present study attempts to evaluate the potential beneficial effects of a flavonoid, the epigallocatechingallate, on retinal ganglion cell function, evaluated by pattern electroretinogram, in subjects with ocular hypertension or early glaucoma.

Condition Intervention Phase
Primary Open Angle Glaucoma Ocular Hypertension Drug: Epigallocatechin-gallate Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Supportive Care
Official Title: Functional Effects of Epigallocatechingallate on Retinal Function in Glaucoma

Resource links provided by NLM:

Further study details as provided by Catholic University of the Sacred Heart:

Primary Outcome Measures:
  • PERG [ Time Frame: six months ]

Secondary Outcome Measures:
  • IOP [ Time Frame: six months ]
  • Optical Coherence Tomography measurements of retinal nerve fiber layer thickness [ Time Frame: six months ]

Estimated Enrollment: 40
Study Start Date: November 2006
Estimated Study Completion Date: July 2008
  Show Detailed Description


Ages Eligible for Study:   35 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • IOP > 21 mmHg at the time of diagnosis
  • Response to ipotensive therapy
  • No visible alterations of the optical nerve head (if OHT)
  • Visual field: normal (if OHT), < -6dB at diagnosis (if POAG)
  • Alterations in PERG
  • Familiarity for glaucoma (if OHT)

Exclusion Criteria:

  • Change of ipotensive therapy
  • Ocular surgery
  • Other ocular pathologies
  • Smokers
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00476138

Contact: Benedetto Falsini, M.D. 01139-06-3015 ext 6344
Contact: Emilio Balestrazzi, M.D. 01139-06-3015 ext 4929

Catholic University, Policlinico A. Gemelli (Hospital) Recruiting
Rome, Italy, 00168
Contact: Benedetto Falsini, M.D.    01139-06-3015 ext 4929   
Sponsors and Collaborators
Catholic University of the Sacred Heart
Principal Investigator: Benedetto Falsini, MD Chatolic University of Sacred Heart, Roma
Principal Investigator: Tommaso Salgarello, M.D. Catholic University, Italy
Principal Investigator: Dario Marangoni, M.D. Catholic University, Italy
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00476138     History of Changes
Other Study ID Numbers: FISIONERVE-01
Study First Received: May 18, 2007
Last Updated: May 18, 2007

Keywords provided by Catholic University of the Sacred Heart:
Optic Nerve
Pattern Electroretinogram
Retinal Ganglion Cells

Additional relevant MeSH terms:
Glaucoma, Open-Angle
Ocular Hypertension
Vascular Diseases
Cardiovascular Diseases
Eye Diseases
Epigallocatechin gallate
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Antimutagenic Agents
Anticarcinogenic Agents
Antineoplastic Agents
Neuroprotective Agents processed this record on August 18, 2017